INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Matrix Service Company - MTRX

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Matrix Service Company (“Matrix” or the “Company”) (NASDAQ: MTRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Matrix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 9, 2025, Matrix issued a press release announcing its fiscal year 2025 fourth quarter and full-year results.  For the quarter, Matrix reported non-GAAP earnings per share of -$0.28, missing consensus estimates by $0.29, and revenue of $216.4 million, missing consensus estimates by $15.85 million.  Matrix stated that “[o]ur fourth quarter net income reflects a $14.9 million impact associated with four issues: a charge related to labor cost overruns on a crude oil terminal project, which is now complete; an updated reserve to a contract dispute on a project dating back to the pandemic, currently in arbitration; a charge for an unfavorable court decision related to a subcontractor’s failure to pay lower tier contractors for another pandemic era project; and restructuring costs related to our organizational realignment.” 

On this news, Matrix’s stock price fell $1.98 per share, or 13.89%, to close at $12.27 per share on September 10, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galiano Gold Inc. - GAU

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Galiano Gold Inc. (“Galiano” or the “Company”) (NYSE: GAU).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Galiano and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 9, 2025, Galiano issued a press release describing “an incident that occurred at its Asanko Gold Mine” in Ghana, which “involved a confrontation between community members and military personnel on the Company’s operating concessions[.]”  Galiano stated that “[t]ensions escalated within the local community, leading to civil unrest, including a fatality and damage to contractor equipment.” 

On this news, Galiano’s stock price fell $0.18 per share, or 7.03%, to close at $2.38 per share on September 10, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lesaka Technologies, Inc. - LSAK

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Lesaka Technologies, Inc. (“Lesaka” or the “Company”) (NASDAQ: LSAK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Lesaka and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 10, 2025, Lesaka disclosed in a filing with the U.S. Securities and Exchange Commission (“SEC”) that the Audit Committee of its Board of Directors had “concluded that the Company’s unaudited condensed consolidated financial statements for the quarters ended September 30, 2024, December 31, 2024, and March 31, 2025, respectively, included in the Company’s Quarterly Reports on Form 10-Q for the quarters ended September 30, 2024, December 31, 2024, and March 31, 2025, respectively (the “Quarterly Reports”), should be restated, and that such unaudited condensed financial statements should no longer be relied upon, due to the Company’s re-evaluation of the classification of certain revenue that has been reported as an agent rather than as principal, and related cost of goods sold.” 

On this news, Lesaka’s stock price fell $0.48 per share, or 10.15%, to close at $4.25 per share on September 11, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Synopsys, Inc. - SNPS

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Synopsys, Inc. (“Synopsys” or the “Company”) (NASDAQ: SNPS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Synopsys and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 9, 2025, Synopsys issued a press release reporting its financial results for the third quarter of its 2025 fiscal year.  In the press release, Synopsys’s Chief Executive Officer stated that “our IP business underperformed expectations” and said that the Company was “taking a more conservative view of Q4, while guiding another year of profitable growth.”  Following these announcements, Baird downgraded Synopsys’s rating to Neutral from Outperfrom and lowered its price target to $535 from $670.

On this news, Synopsys’s stock price fell $216.59 per share, or 35.84%, to close at $387.78 per share on September 10, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PACS Group, Inc. - PACS

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  PACS Group, Inc. (“PACS” or the “Company”) (NYSE: PACS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether PACS and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 8, 2025, PACS announced the resignation of Derick Apt “from his role as Chief Financial Officer” after “the Audit Committee of the Company’s board of directors became aware of allegations that Mr. Apt had accepted a series of high-value items from individuals associated with a group of related entities with which the Company does business” and subsequently found “that Mr. Apt’s receipt of these items of value violated company policies, including the Company’s Code of Conduct.” 

On this news, PACS’s stock price fell $3.29 per share, or 29.08%, to close at $8.03 per share on September 9, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  AVITA Medical, Inc. (“Avita” or the “Company”) (NASDAQ: RCEL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Avita and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 7, 2025, Avita reported its financial results for the second quarter of 2025.  Among other items, Avita disclosed “a six-month backlog in unpaid provider claims for Recell procedures impacted first-half demand.”  Avita explained that contractors assigned by the Centers for Medicare & Medicaid Services to determine pricing of Recell “neither assigned a price or assigned an inadequate price and failed to adjudicate claims in a timely manner.”  Accordingly, “claims accumulated from January through June, creating a significant backlog of unpaid claims and inadequately paid claims to providers for Recell procedures.  This lack of resolution created uncertainty among providers regarding payment expectations and timelines, which led to a reduction in Recell utilization during the first half of the year.” 

On this news, Avita’s stock price fell $1.13 per share, or 21%, to close at $4.25 per share on August 8, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 30, 2025, Summit issued a press release “announc[ing] topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab[.]”  Although patients treated with ivonescimab and chemotherapy were 48% less likely to progress or die than patients who received chemo alone, the drug failed to make a statistically significant difference in overall survival, a metric that measures how long patients live before dying of any cause. 

On this news, Summit’s stock price fell $7.99 per share, or 30.5%, to close at $18.22 per share on May 30, 2025. 

Then, on September 7, 2025, Summit announced additional data from the trial, in which ivonescimab produced weaker results in patients from North America and Europe than in those from Europe. 

On this news, Summit’s stock price fell $6.54 per share, or 25.15%, to close at $19.45 per share on September 8, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether Agios and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 4, 2025, Agios issued a press release “announc[ing] that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three months to December 7, 2025.”  

On news of the delayed review, Agios’s stock price fell $4.48 per share, or 11.03%, to close at $36.13 per share on September 4, 2025.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes. 

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Cybin Inc. (“Cybin” or the “Company”) (NYSE: CYBN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Cybin and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

We are investigating Cybin Inc. (CYBN) (“Cybin” or the “Company”) for potential violations of the federal securities laws.  On September 2, 2025, Cybin issued a press release “annnounc[ing] that, effective September 2, 2025, Doug Drysdale will step down as the Company’s Chief Executive Officer.” 

On this news, Cybin’s stock price fell $1.24 per share, or 16.58%, to close at $6.24 per share on September 2, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skillz Inc.– SKLZ

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Skillz Inc. (“Skillz” or the “Company”) (NYSE: SKLZ).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether Skillz and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 2, 2025, Skillz disclosed in a filing with the U.S. Securities and Exchange Commission that Tether Studios and its affiliate Tether Games (together, “Tether”) plan to terminate all agreements with Skillz, effective September 1, 2025.  Under the agreements, Skillz has licensed its software to Tether for use in monetizing Tether’s games.  In return, both companies share the revenue from user entry fees.  After receiving the notice, Skillz filed a lawsuit on September 1, 2025, seeking to block Tether’s termination of their agreements.  Skillz is also disputing Tether’s reasons for ending the deal. 

On this news, Skillz’s stock price fell $1.50 per share, or 17.22%, to close at $7.21 per share on September 3, 2025.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes. 

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EHang Holdings Limited - EH

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  EHang Holdings Limited (“EHang” or the “Company”) (NASDAQ: EH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether EHang and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 26, 2025, EHang reduced its 2025 revenue projection to 500 million yuan from 900 million yuan, prompting Morgan Stanley to lower its forecasts for the Company. 

On this news, EHang’s American Depositary Receipt (“ADR”) price fell $1.34 per ADR, or 7.53%, to close at $16.45 per ADR on August 26, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Axogen, Inc. (“Axogen” or the “Company”) (NASDAQ: AXGN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Axogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 25, 2025, Axogen issued a press release “announc[ing] that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by three months to December 5, 2025.” 

On this news, Axogen’s stock price fell $1.47 per share, or 9.04%, to close at $14.79 per share on August 25, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Valneva and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On February 25, 2025, the U.S. Centers for Disease Control and Prevention (“CDC”) posted a notice on its website announcing that “CDC is currently investigating five hospitalizations for cardiac or neurologic events following vaccination with IXCHIQ [Valneva’s chikungunya virus vaccine] among people 65 years of age and older.” 

Following the CDC’s announcement and subsequent reporting by media outlets, Valneva’s American Depositary Receipt (“ADR”) price fell $1.06 per ADR, or 13.57%, over the following four trading sessions, to close at $6.75 per ADR on February 28, 2025. 

Then, on August 22, 2025, the U.S. Food and Drug Administration announced that it had suspended the marketing application for IXCHIQ due to safety concerns. 

On this news, Valneva’s ADR price fell $2.21 per ADR, or 18.99%, to close at $9.43 per ADR on August 25, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Coty Inc. – COTY

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Coty Inc. (“Coty” or the “Company”) (NYSE: COTY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether Coty and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 20, 2025, Coty issued a press release reporting its financial results its full fiscal year 2025 and fourth quarter.  Among other items, Coty reported an unexpected loss and provided disappointing guidance.  Discussing the results on an earnings call, Coty’s Chief Financial Officer said that “[t]he challenges of fiscal year 2025 coincided with moderating profit in the broader beauty market,” attributing sluggish sales to factors ranging from value-seeking behavior, innovation fatigue by consumers, and anti-theft and immigration policy changes. 

On this news, Coty’s stock price fell $1.05 per share, or 21.6%, to close at $3.81 per share on August 21, 2025.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes. 

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Soleno and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 15, 2025, Scorpion Capital (“Scorpion”) published a report that described Soleno’s only product, Vykat XR, as overpriced and potentially unsafe for children. 

Following publication of the Scorpion report, Soleno’s stock price fell $5.73 per share, or 7.41%, to close at $71.63 per share on August 15, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Roblox Corporation – RBLX

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Roblox Corporation (“Roblox” or the “Company”) (NYSE: RBLX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether Roblox and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 14, 2025, Louisiana Attorney General Liz Murrill filed a lawsuit against Roblox, alleging that the lack of controls on the Company’s online gaming platform “allow[s] child predators to pose as children and for children to bypass any age requirement”, thereby creating an unchecked forum for sexual predators to connect with children and facilitating the sharing of sexually explicit material. 

As media outlets reported on the lawsuit, Roblox’s stock price fell $7.94 per share, or 6.34%, to close at $117.34 per share on August 15, 2025.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes. 

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Align Technology, Inc. – ALGN

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Align Technology, Inc. (“Align” or the “Company”) (NASDAQ: ALGN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether Align and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On July 30, 2025, Align issued a press release announcing its financial results for the second quarter of 2025.  Among other items, Align reported total revenues of approximately $1.01 billion, missing both consensus estimates and the Company’s own guidance.  Align also lowered its third-quarter revenue guidance and full-year growth expectations, citing “the potential continued economic uncertainty and spending hesitancy that impacted demand for our clear aligners and new iTero scanner systems in the second quarter.” 

On this news, Align’s stock price fell $74.56 per share, or 36.63%, to close at $129.01 per share on July 31, 2025.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes. 

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innovative Solutions and Support, Inc. - ISSC

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Innovative Solutions and Support, Inc. (“IS&S” or the “Company”) (NASDAQ: ISSC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether IS&S and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 14, 2025, IS&S issued a press release announcing its financial results for its fiscal third quarter of 2025.  Therein, the Company’s Chief Executive Officer Shahram Askarpour advised, among other things, that a “pull-forward of F-16 production into the current quarter . . . will impact revenue over the next two quarters[.]” 

On this news, IS&S’s stock price fell $6.22 per share, or 31.53%, to close at $13.51 per share on August 14, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.    

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Broadwind, Inc. - BWEN

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Broadwind, Inc. (“Broadwind” or the “Company”) (NASDAQ: BWEN).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Broadwind and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 12, 2025, Broadwind issued a press release announcing its financial results for the second quarter of 2025.  Among other results, the Company reported a GAAP loss per share of $0.04 for the quarter, missing consensus estimates by $0.05.  The Company also suspended its previously issued full-year 2025 financial guidance as a result of a definitive agreement that it had entered into to sell its industrial fabrication operations in Manitowoc, Wisconsin.

On this news, Broadwind’s stock price fell $0.36 per share, or 14.46%, to close at $2.13 per share on August 12, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stitch Fix, Inc. - SFIX

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Stitch Fix, Inc. (“Stitch Fix” or the “Company”) (NASDAQ: SFIX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Stitch Fix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 24, 2025, Stitch Fix issued a press release announcing its financial results for the fourth quarter and full fiscal year 2025, ended August 2, 2025.  Among other items, Stitch Fix reported a fifteenth consecutive quarter of subscriber loss, along with weakening gross margin rates and advertising spending that is reaching 10% of revenue.  During an accompanying earnings call, the Company’s Chief Financial Officer warned that Stitch Fix is entering the holiday season with a “challenging macro environment,” and a narrower profit margin due to higher transportation costs and “ongoing strategic investments in our client experience and assortment.” 

On this news, Stitch Fix’s stock price fell $0.93 per share, or 16.49%, to close at $4.71 per share on September 25, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.